P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)

• J. Y. Chen,
• L. Johnson,
• K. M. McKenna,
• T. S. Choi,
• J. Duan,
• D. Feng,
• J. M. Tsai,
• N. Garcia-Martin,
• K. Sompalli,
• R. Maute,
• P. Vyas,
• R. Majeti,
• C. H. M. Takimoto,
• J. Liu,
• G. Ramsingh,
• M. P. Chao,
• J.-P. Volkmer,
• I. L. Weissman

Affiliations

J. Y. Chen

1 Stanford University School of Medicine, Stanford

L. Johnson

2 Gilead Sciences, Inc., Foster City

K. M. McKenna

2 Gilead Sciences, Inc., Foster City

T. S. Choi

2 Gilead Sciences, Inc., Foster City

J. Duan

2 Gilead Sciences, Inc., Foster City

D. Feng

2 Gilead Sciences, Inc., Foster City

J. M. Tsai

3 Brigham and Women’s Hospital, Boston, United States of America

N. Garcia-Martin

4 Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

K. Sompalli

2 Gilead Sciences, Inc., Foster City

R. Maute

2 Gilead Sciences, Inc., Foster City

P. Vyas

4 Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

R. Majeti

5 Ludwig Cancer Center and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, United States of America

C. H. M. Takimoto

2 Gilead Sciences, Inc., Foster City

J. Liu

1 Stanford University School of Medicine, Stanford

G. Ramsingh

2 Gilead Sciences, Inc., Foster City

M. P. Chao

2 Gilead Sciences, Inc., Foster City

J.-P. Volkmer

2 Gilead Sciences, Inc., Foster City

I. L. Weissman

5 Ludwig Cancer Center and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, United States of America